rAAV vector production core — IBCCF/UFRJ
Vector Core
The first national recombinant adeno-associated virus (rAAV) vector production core was established by Prof. Hilda Petrs-Silva at IBCCF, enabling preclinical and clinical gene therapy research in Brazil without dependence on imported vectors. The core combines large-scale technical capacity with expertise in capsid engineering and in vivo biological validation.
Technical capabilities
Custom-built vectors
Available serotypes
AAV1, AAV2, AAV5, AAV8, AAV9, and tyrosine-mutants (Y444F, Y500F, Y730F).
Vector construction
Design and cloning of rAAV-ITR plasmids with specific promoters (CBA, CMV, custom mini-promoters for ganglion cells).
Large-scale production
Triple transfection in HEK293 with iodixanol gradient purification and qPCR titration.
In vivo validation
Transduction analysis in retina and CNS via intravitreal, intravenous, or intrastriatal injection — with GFP/luciferase readout.
Advanced engineering
Capsids with targeting peptides (phage display), CRISPR-Cas9, and CRISPR-a packaged in rAAV.
Collaborations
We serve academic researchers from UFRJ and partner institutions (USP, UFMG, UFRGS, UFF). For collaboration projects or vector requests, please contact Prof. Hilda by email.
Request collaboration